ABSTRACT
No disponible
Subject(s)
Humans , Coronavirus Infections/epidemiology , Coronavirus Infections/microbiology , Pneumonia, Viral/epidemiology , Pneumonia, Viral/microbiology , Travelers' Health , Pandemics , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Diagnosis, Differential , Communicable Diseases, Imported/epidemiologySubject(s)
COVID-19/transmission , Pandemics , SARS-CoV-2 , Tourism , Travel-Related Illness , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19 Testing , Communicable Diseases, Emerging/prevention & control , Communicable Diseases, Emerging/transmission , Communicable Diseases, Imported/prevention & control , Communicable Diseases, Imported/transmission , Global Health , Humans , Mass Screening , Travel/legislation & jurisprudenceABSTRACT
No disponible
Subject(s)
Humans , Male , Female , Adolescent , Norovirus/pathogenicity , Caliciviridae Infections/epidemiology , Gastroenteritis/microbiology , Disease OutbreaksSubject(s)
Caliciviridae Infections/epidemiology , Disease Outbreaks , Gastroenteritis/epidemiology , Gastroenteritis/virology , Norovirus , Acute Disease , Adolescent , Child , Female , Humans , Male , Schools , Spain/epidemiology , Young AdultABSTRACT
Objetivo: Evaluar un nuevo inmunoensayo quimioluminiscente de micropartículas (ARCHITECT Chagas®, Abbott). Métodos Estudio aleatorio con 165 muestras mediante 2 técnicas serológicas diferentes. El ensayo ARCHITECT Chagas® se realizó empleando el sistema ARCHITECT i2000SR (Abbott).Resultados La sensibilidad y la especificidad del ensayo ARCHITECT fueron del 100 y del 96,6%, respectivamente. El índice de concordancia con las técnicas ELISA e IFI fue de 0,96 (IC95%: 0,92-1) y 0,91 (IC95%: 0,85-0,97), respectivamente. Conclusiones El ensayo ARCHITECT Chagas® demuestra tener una sensibilidad y una especificidad similares a los tests ELISA e IFI; permite además procesar un mayor número de muestras con una mayor estandarización y reproducibilidad de los resultados, así como una interpretación totalmente objetiva de los mismos (AU)
Objective: To evaluate a new chemiluminescent microparticle immunoassay (ARCHITECT Chagas®, Abbott).Methods: In this study, 165 samples were tested by two different serological tests. The ARCHITECT Chagas®assay was performed using ARCHITECT i2000SR system (Abbott).Results: The sensitivity and speciflcity of ARCHITECT assay was 100% and 96.6%, respectively. The concordance rate was 0.96 (95% CI: 0.92-1) for ELISA and 0.91 (95% CI: 0.85-0.97) for immunofluorescence assay (IFA).Conclusions: The ARCHITECT Chagas®assay demonstrates a sensitivity and speciflcity similar to ELISA and IFA assays; it allows a large volume of samples to be processed with a good standardization and reproducibility, as well as an objective interpretation (AU)
Subject(s)
Humans , Chagas Disease/immunology , Immunoassay/methods , Trypanosoma cruzi/isolation & purification , Reproducibility of Results , Sensitivity and SpecificityABSTRACT
OBJECTIVE: To evaluate a new chemiluminescent microparticle immunoassay (ARCHITECT Chagas(®), Abbott). METHODS: In this study, 165 samples were tested by two different serological tests. The ARCHITECT Chagas(®) assay was performed using ARCHITECT i2000(SR) system (Abbott). RESULTS: The sensitivity and specificity of ARCHITECT assay was 100% and 96.6%, respectively. The concordance rate was 0.96 (95%CI: 0.92-1) for ELISA and 0.91 (95%CI: 0.85-0.97) for immunofluorescence assay (IFA). CONCLUSIONS: The ARCHITECT Chagas(®) assay demonstrates a sensitivity and specificity similar to ELISA and IFA assays; it allows a large volume of samples to be processed with a good standardization and reproducibility, as well as an objective interpretation.
